FY2016 Earnings Estimate for Theravance Biopharma Inc. Issued By Leerink Swann (TBPH)
Theravance Biopharma Inc. (NASDAQ:TBPH) – Leerink Swann raised their FY2016 earnings per share estimates for shares of Theravance Biopharma in a research note issued to investors on Wednesday. Leerink Swann analyst G. Porges now expects that the firm will post earnings of ($3.68) per share for the year, up from their previous forecast of ($4.19). Leerink Swann currently has a “Buy” rating and a $33.00 price objective on the stock. Leerink Swann also issued estimates for Theravance Biopharma’s Q4 2016 earnings at ($0.92) EPS, FY2017 earnings at ($3.58) EPS and FY2018 earnings at ($3.77) EPS.
A number of other analysts have also commented on the company. Bank of America Corp. lowered Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 3rd. Robert W. Baird cut Theravance Biopharma from a “neutral” rating to an “underperform” rating and raised their target price for the stock from $19.00 to $24.00 in a report on Wednesday, October 12th. Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday, October 14th. Guggenheim restated a “positive” rating and set a $40.00 target price on shares of Theravance Biopharma in a report on Monday, September 19th. Finally, Evercore ISI initiated coverage on Theravance Biopharma in a report on Monday, August 29th. They set a “buy” rating and a $41.00 target price on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Theravance Biopharma currently has an average rating of “Hold” and a consensus price target of $36.83.
Theravance Biopharma (NASDAQ:TBPH) opened at 34.11 on Friday. The company has a 50-day moving average price of $31.98 and a 200-day moving average price of $26.41. Theravance Biopharma has a 12-month low of $12.87 and a 12-month high of $38.92. The firm’s market cap is $1.63 billion.
In other news, SVP Brett K. Haumann sold 4,491 shares of Theravance Biopharma stock in a transaction dated Thursday, August 25th. The stock was sold at an average price of $27.99, for a total transaction of $125,703.09. Following the transaction, the senior vice president now owns 188,293 shares in the company, valued at approximately $5,270,321.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brett K. Haumann sold 9,509 shares of Theravance Biopharma stock in a transaction dated Friday, August 19th. The shares were sold at an average price of $27.97, for a total value of $265,966.73. Following the transaction, the senior vice president now owns 197,391 shares in the company, valued at approximately $5,521,026.27. The disclosure for this sale can be found here. Insiders own 4.70% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in TBPH. BNP Paribas Arbitrage SA boosted its position in Theravance Biopharma by 110.2% in the third quarter. BNP Paribas Arbitrage SA now owns 3,008 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,577 shares during the period. Strs Ohio purchased a new stake in shares of Theravance Biopharma during the third quarter worth about $134,000. Teacher Retirement System of Texas raised its stake in shares of Theravance Biopharma by 40.2% in the second quarter. Teacher Retirement System of Texas now owns 4,887 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 1,401 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 192 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of Theravance Biopharma during the second quarter worth about $255,000. Institutional investors and hedge funds own 70.02% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.